Patents Assigned to Sigma-Tau
  • Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
    Patent number: 8101793
    Abstract: Are described compounds of Formula (I) in which R, R?, R?, A, and D have the meanings described in the text, as useful agents in the cure of pathologies characterized by altered angiogenesis and as antitumorals.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: January 24, 2012
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Lucio Merlini, Sabrina Dallavalle, Sergio Penco, Giuseppe Giannini, Claudio Pisano, Loredana Vesci
  • Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
    Patent number: 8067555
    Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives have antiangiogenic and heparanase-inhibiting activity and are devoid of anticoagulant activity.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: November 29, 2011
    Assignee: Sigma-Tau Research Switzerland S.A.
    Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
  • Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
    Patent number: 8053472
    Abstract: The invention relates to the use of the acetyl L-carnitine in association with the biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: November 8, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Menotti Calvani
  • Indole derivatives having antitumor activity
    Patent number: 8053460
    Abstract: Indole derivatives of Formula (I+A) having antitumor and chemosensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumors.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: November 8, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Pisano, Gianfranco Battistuzzi, Maria Di Marzo, Giuseppe Giannini, Mauro Marzi, Loredana Vesci, Franco Zunino
  • COMPOUNDS USEFUL FOR THE PREVENTION OR TREATMENT OF ACCOMODATIVE ASTHENOPIA
    Publication number: 20110268817
    Abstract: It is described the use of L-carnitine, in combination with antioxidants such as vitamin E and inorganic elements such as manganese, zinc, sodium and potassium, for the preparation of a physiological supplement or medicament for opthalmic use, for the prevention or treatment of accomodative asthenopia.
    Type: Application
    Filed: June 25, 2009
    Publication date: November 3, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Nicola Pescosolido, Aleardo Koverech
  • Anti-human tenascin monoclonal antibody
    Patent number: 8048417
    Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: November 1, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: De Santis Rita, Anastasi Anna Maria
  • COMPOSITION USEFUL FOR THE PREVENTION OR REDUCTION OF THE PROGRESSION OF PROSTATE CANCER
    Publication number: 20110262417
    Abstract: It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer.
    Type: Application
    Filed: July 24, 2009
    Publication date: October 27, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Franco Gaetani, Ashraf Virmani
  • Aminoderivative of biotin and their conjugates with macrocyclic chelating agents
    Patent number: 8044081
    Abstract: Formula (I) compounds are described where the groups are as defined here below, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: October 25, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Giovanni Paganelli, Marco Chinol, Mauro Ginanneschi
  • ARYL ISOXAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITIES
    Publication number: 20110245221
    Abstract: The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 30, 2009
    Publication date: October 6, 2011
    Applicant: SIGMA-TAU RESEARCH SWITZERLAND S.A.
    Inventors: Giuseppe Giannini, Walter Cabri, Daniele Simoni, Riccardo Baruchello, Paolo Carminati, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati, Claudio Pisano
  • Use of thymosin alpha 1 for the treatment of immunological diseases
    Patent number: 8022036
    Abstract: It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: September 20, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Luigina Romani, Francesco Bistoni, Enrico Garaci
  • Amino derivatives of beta-homoandrostanes and beta-heteroandrostanes
    Patent number: 8022203
    Abstract: New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: September 20, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Alberto Cerri, Barbara Moro, Maco Torri, Giulio Carzana, Giuseppe Bianchi, Mara Ferrandi, Patrizia Ferrari, Maria Pia Zappavigna, Leonardo Banfi, Giuseppe Giacalone
  • COMPOUND USEFUL FOR TREATING CELLULITE
    Publication number: 20110217252
    Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.
    Type: Application
    Filed: November 5, 2009
    Publication date: September 8, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventor: Aleardo Koverech
  • Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome
    Patent number: 8013016
    Abstract: The use of acetyl L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicament and/or dietetic product for the treatment of fibromyalgic syndrome.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: September 6, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Aleardo Koverech
  • Pharmaceutical compositions containing the long pentraxin PTX3
    Patent number: 8003109
    Abstract: Pharmaceutical compositions are described containing a long pentraxin PTX3, particularly human PTX3, for the therapy of infectious and inflammatory or tumor diseases; expression vectors containing cDNA coding for PTX3; recombinant host cells transfected with such vectors; a method for producing substantial amounts of PTX3 involving the culturing of such cells, and the use of said vectors in the gene therapy of tumors.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: August 23, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Barbara Bottazzi, Martino Introna, Alberto Mantovani, Annunciata Vecchi
  • Use of acetyl L-carnitine in combination with propionyl L-carnitine and Sildenafil for the treatment of erectile dysfunction
    Patent number: 8003652
    Abstract: The use of acetyl L-carnitine in combination with propionyl L-carnitine and sildenafil is described for the preparation of a medicament and/or dietetic product for the treatment of erectile dysfunction secondary to all those conditions in which there is distress or iatrogenic damage of the lesser pelvis within which the neurovascular bundles of the penis run.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: August 23, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite, S.p.A.
    Inventors: Aleardo Koverech, Giorgio Cavallini
  • Vector for efficient selection and/or maturation of an antibody and uses thereof
    Patent number: 8003383
    Abstract: It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: August 23, 2011
    Assignees: Sigma Tau Industrie Farmaceutiche Riunite S.pA., Tecnogen S.p.A.
    Inventors: Olga Minenkova, Emiliano Pavoni
  • Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
    Publication number: 20110189152
    Abstract: A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.
    Type: Application
    Filed: February 7, 2011
    Publication date: August 4, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Mohamed Ashraf Virmani, Aleardo Koverech
  • Solution containing carnitine for the storage and perfusion of organs awaiting transplantation
    Patent number: 7989158
    Abstract: A storage solution to maintain and perfuse organs awaiting transplantation comprising (a) an isotonic balanced solution comprising a physiologically acceptable amount of potassium, mono acidic phosphate, biacidic phosphate, chloride, sodium and bicarbonate ions; (b) 50-250 mM glucose; (c) 0.2-20 mM of an alkanoyl L-carnitine or a physiologically acceptable salt thereof; (d) 1-100 mM of L-carnitine or a physiologically acceptable salt thereof; (e) water is described. The storage solution can also include other components such as anti-oxidants and/or chelating agents.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: August 2, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Arduini Arduino, Aureli Tommaso
  • NOVEL DUAL TARGETING ANTITUMORAL CONJUGATES
    Publication number: 20110160147
    Abstract: The present invention relates to dual-targeting cytotoxic compounds of formula (I) and to their preparation. The described compounds are endowed with tumour specific action, incorporating three functional units: a tumour recognition moiety and a tumour selective enzymatic substrate sequence connected together by means of a spacer. These conjugates are designed to guarantee serum stability and, at the same time, the desired action inside the tumour cells as a result of enzymatic cleavability. [(L-D)nE]m-F-D-PI-SI-CT Formula (I).
    Type: Application
    Filed: September 2, 2009
    Publication date: June 30, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Alma Dal Pozzo, Emiliano Esposito, Minghong Ni, Sergio Penco, Claudio Pisano, Massimo Castorina, Loredana Vesci
  • CRYSTALLINE TEGLICAR
    Publication number: 20110136905
    Abstract: The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same.
    Type: Application
    Filed: July 31, 2008
    Publication date: June 9, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Walter Cabri, Mauro Marzi, Fabrizio Giorgi, Emanuela Tassoni